98 related articles for article (PubMed ID: 16092970)
1. Efficient trapping of HIV-1 envelope protein by hetero-oligomerization with an N-helix chimera.
Ou W; Silver J
Retrovirology; 2005 Aug; 2():51. PubMed ID: 16092970
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of murine leukemia virus envelope protein (env) processing by intracellular expression of the env N-terminal heptad repeat region.
Ou W; Silver J
J Virol; 2005 Apr; 79(8):4782-92. PubMed ID: 15795264
[TBL] [Abstract][Full Text] [Related]
3. The role of the N-terminal heptad repeat of HIV-1 in the actual lipid mixing step as revealed by its substitution with distant coiled coils.
Wexler-Cohen Y; Sackett K; Shai Y
Biochemistry; 2005 Apr; 44(15):5853-61. PubMed ID: 15823044
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of the placental fusogenic membrane protein syncytin.
Chang C; Chen PT; Chang GD; Huang CJ; Chen H
Biol Reprod; 2004 Dec; 71(6):1956-62. PubMed ID: 15269105
[TBL] [Abstract][Full Text] [Related]
5. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
6. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
7. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
8. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion.
Ablan S; Rawat SS; Viard M; Wang JM; Puri A; Blumenthal R
Virol J; 2006 Dec; 3():104. PubMed ID: 17187670
[TBL] [Abstract][Full Text] [Related]
9. Antiviral properties of two trimeric recombinant gp41 proteins.
Delcroix-Genête D; Quan PL; Roger MG; Hazan U; Nisole S; Rousseau C
Retrovirology; 2006 Mar; 3():16. PubMed ID: 16515685
[TBL] [Abstract][Full Text] [Related]
10. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro.
Pang W; Wang RR; Yang LM; Liu CM; Tien P; Zheng YT
Virology; 2008 Jul; 377(1):80-7. PubMed ID: 18499209
[TBL] [Abstract][Full Text] [Related]
11. [1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane].
Sun W; Wang HT; Xia CL; Wu SG; Jiang SB; Jiang ZH; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1127-31. PubMed ID: 18676243
[TBL] [Abstract][Full Text] [Related]
12. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
13. Retrocyclin RC-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41.
Fuhrman CA; Warren AD; Waring AJ; Dutz SM; Sharma S; Lehrer RI; Cole AL; Cole AM
FEBS J; 2007 Dec; 274(24):6477-87. PubMed ID: 18028423
[TBL] [Abstract][Full Text] [Related]
14. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine.
Hout DR; Gomez LM; Pacyniak E; Miller JM; Hill MS; Stephens EB
Virology; 2006 May; 348(2):449-61. PubMed ID: 16458946
[TBL] [Abstract][Full Text] [Related]
15. Evidence that insertion of Tomato ringspot nepovirus NTB-VPg protein in endoplasmic reticulum membranes is directed by two domains: a C-terminal transmembrane helix and an N-terminal amphipathic helix.
Zhang SC; Zhang G; Yang L; Chisholm J; Sanfaçon H
J Virol; 2005 Sep; 79(18):11752-65. PubMed ID: 16140753
[TBL] [Abstract][Full Text] [Related]
16. Direct Vpr-Vpr interaction in cells monitored by two photon fluorescence correlation spectroscopy and fluorescence lifetime imaging.
Fritz JV; Didier P; Clamme JP; Schaub E; Muriaux D; Cabanne C; Morellet N; Bouaziz S; Darlix JL; Mély Y; de Rocquigny H
Retrovirology; 2008 Sep; 5():87. PubMed ID: 18808682
[TBL] [Abstract][Full Text] [Related]
17. CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.
Imamura S; Kurasawa O; Nara Y; Ichikawa T; Nishikawa Y; Iida T; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2004 May; 12(9):2295-306. PubMed ID: 15080927
[TBL] [Abstract][Full Text] [Related]
18. Expression of a modified form of CD4 results in the release of an anti-HIV factor derived from the Env sequence.
Zaldívar I; Muñoz-Fernández MA; Alarcón B; San José E
J Immunol; 2009 Jul; 183(2):1188-96. PubMed ID: 19553524
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.
Imai M; Baranyi L; Okada N; Okada H
Biochem Biophys Res Commun; 2007 Feb; 353(4):851-6. PubMed ID: 17210123
[TBL] [Abstract][Full Text] [Related]
20. Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex.
Lorizate M; Gómara MJ; de la Torre BG; Andreu D; Nieva JL
J Mol Biol; 2006 Jun; 360(1):45-55. PubMed ID: 16813835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
